Immune checkpoint inhibitors (ICIs) may be superior to chemotherapy as second-line treatment for malignant pleural mesothelioma (MPM), according to research published in Lung Cancer.

The researchers noted that ICIs have produced mixed results as second-line therapy in MPM trials, so the team set out to evaluate the effectiveness of second-line ICIs in a real-world setting.

The researchers conducted a retrospective cohort study of 176 patients with MPM who received second-line therapy from 2015 to 2019. The patients’ median age was 75 years, 77% of patients were White, 74% were men, and 67% had epithelioid histology.


Continue Reading

There were 115 patients who received ICI treatment and 61 patients who received chemotherapy. In the ICI group, 80 patients received pembrolizumab, 31 received nivolumab, and 4 received nivolumab plus ipilimumab. In the chemotherapy group, 48 patients received gemcitabine, 11 received vinorelbine, and 2 received gemcitabine plus vinorelbine.

The median overall survival was significantly longer with ICIs than with chemotherapy — 8.7 months and 5 months, respectively (adjusted hazard ratio, 0.52; 95% CI, 0.34-0.81; P =.001). The estimated 12-month overall survival rate was 36.7% and 15.6%, respectively.

The overall mortality rate was 91.8% among patients who received chemotherapy and 79.1% among patients who received ICIs (P =.031).

“Our findings suggest that ICI may benefit patients with advanced MPM and progression after initial platinum-based chemotherapy,” the researchers wrote. “Further investigation is needed to determine the role of ICI therapy in MPM patients with disease progression after first-line therapy and if outcomes vary by histologic subtype.”

Reference

Kim RY, Li Y, Marmarelis ME, Vachani A. Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma. Lung Cancer. Published online July 17, 2021. doi:10.1016/j.lungcan.2021.06.017

This article originally appeared on Cancer Therapy Advisor